<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221035</url>
  </required_header>
  <id_info>
    <org_study_id>2019-001068-31</org_study_id>
    <secondary_id>2019/2894</secondary_id>
    <nct_id>NCT04221035</nct_id>
  </id_info>
  <brief_title>High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)</brief_title>
  <acronym>HR-NBL2</acronym>
  <official_title>High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international multicenter, open-label, randomized phase III trial including three&#xD;
      sequential randomizations to assess efficacy of induction and consolidation chemotherapies&#xD;
      and radiotherapy for patients with high-risk neuroblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an international multicenter, open-label, randomized phase III trial including three&#xD;
      sequential randomizations to assess efficacy of induction and consolidation chemotherapies&#xD;
      and radiotherapy for patients with high-risk neuroblastoma.&#xD;
&#xD;
      The first randomization (R-I) will compare the efficacy of two induction chemotherapies&#xD;
      (RAPID COJEC and GPOH regimens) in a phase III setting. The primary endpoint will be the&#xD;
      3-year EFS from date of randomization . The R-I randomization will be stratified on age,&#xD;
      stage, MYCN status and countries.&#xD;
&#xD;
      The second randomization (R-HDC) will compare the efficacy of single HDC with Bu-Mel versus&#xD;
      tandem HDC with Thiotepa followed by Bu-Mel. The primary endpoint is 3-year EFS calculated&#xD;
      from the date of the R-HDC randomization. The R-HDC randomization will be stratified on the&#xD;
      age, stage, MYCN status, induction chemotherapy regimen, response to induction phase and&#xD;
      countries.&#xD;
&#xD;
      The impact of local treatment in this phase III setting will be assessed, according to the&#xD;
      presence or not of a macroscopic residual disease after surgery and HDC.&#xD;
&#xD;
      In case of macroscopic residual disease, 21.6 Gy radiotherapy to the preoperative tumor bed&#xD;
      will be randomized (R-RTx) versus the same treatment plus a sequential boost of additional&#xD;
      14.4 Gy to the residual tumor. The primary endpoint of R-RTx is 3-year EFS from the date of&#xD;
      the R-RTx randomization. The R-RTx randomization will be stratified on age, stage, MYCN&#xD;
      status, induction chemotherapy regimen, HDC regimen and countries.&#xD;
&#xD;
      In case of no macroscopic residual disease, 21.6 Gy radiotherapy will be delivered to the&#xD;
      preoperative tumor bed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2019</start_date>
  <completion_date type="Anticipated">November 2032</completion_date>
  <primary_completion_date type="Anticipated">November 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival (EFS)</measure>
    <time_frame>Assessed at each end of randomization sequences up to one year</time_frame>
    <description>Event free survival</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>High-Risk Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>phase induction-R-I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R-I: induction regimens RAPID COJEC vs GPOH Assuming a baseline 3-year EFS of 40%, with a sample size of 686 patients (343 in each arm) and a two-sided alpha=5% this trial will have 90% power to demonstrate an improvement of 12% in 3-year EFS, within a recruitment period of 3 years and a minimum follow up of 1.5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase high dose chemotherapy consolidation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R-HDC: consolidation regimen Bu-Mel vs Thiotepa + Bu-Mel The 3-year EFS in the Bu-Mel arm (with immunotherapy) is estimated to be 55%. This study aims to show an improvement of 12% for the Thiotepa + Bu-Mel arm (3-year EFS of 67%). With a recruitment of 448 patients (224 in each arm) over a period of 3 years and a minimum follow-up of 2 years, the power to show a 12% difference is 80% (two-sided logrank test and α=5%).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase of radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R-RTx: 21.6 Gy radiotherapy vs 21.6 Gy + 14.4 Gy boost in patients with macroscopic residual disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>1.5 mg/m^2 (max dose 2 mg)</description>
    <arm_group_label>phase induction-R-I</arm_group_label>
    <other_name>L01CA02</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>750 mg/m^2</description>
    <arm_group_label>phase induction-R-I</arm_group_label>
    <other_name>LO1XA02</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>175 mg/m^2</description>
    <arm_group_label>phase induction-R-I</arm_group_label>
    <other_name>L01CB01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>1050 mg/m^2</description>
    <arm_group_label>phase induction-R-I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vindesine</intervention_name>
    <description>3 mg/m^2/day (max dose 6 mg)</description>
    <arm_group_label>phase induction-R-I</arm_group_label>
    <other_name>L01CA03</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <description>200 mg/m^2/day</description>
    <arm_group_label>phase induction-R-I</arm_group_label>
    <other_name>L01AX04</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>1500 mg/m^2/day</description>
    <arm_group_label>phase induction-R-I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>30 mg/m^2/dose</description>
    <arm_group_label>phase induction-R-I</arm_group_label>
    <other_name>L01DB01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>&lt; 9kg: 1.0 mg/kg/dose 9 kg to &lt; 16 kg : 1.2 mg/kg/dose 16 kg to 23 kg : 1.1 mg/kg/dose &gt;23 kg to 34 kg: 0.95 mg/kg/dose &gt;34 kg: 0.8 mg/kg/dose Infusion IV over 2 hours Administration every 6 hours for a total of 16 doses</description>
    <arm_group_label>Phase high dose chemotherapy consolidation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>140 mg/m^2/dose IV short infusion (15'), at least 24 h after the last busulfan dose</description>
    <arm_group_label>Phase high dose chemotherapy consolidation</arm_group_label>
    <other_name>L01AA03</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>300 mg/m^2/day over 2 hours</description>
    <arm_group_label>Phase high dose chemotherapy consolidation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>21.6 Gy 21.6 Gy + boost de 14.4 Gy</description>
    <arm_group_label>Phase of radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dinutuximab Beta</intervention_name>
    <description>Patients &gt;12 kg are dosed based on the BSA: 10 mg/m^2/day Patients ≤ 12 kg are dosed according to their body weight: 0.33 mg/kg/day</description>
    <arm_group_label>Phase of radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>80 mg/m^2/24h</description>
    <arm_group_label>phase induction-R-I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        At diagnosis (or up to 21 days after one cycle of chemotherapy for patients with localized&#xD;
        neuroblastoma with MYCN amplification).&#xD;
&#xD;
        R-I eligibility criteria:&#xD;
&#xD;
          1. Established diagnosis of neuroblastoma according to the SIOPEN-modified International&#xD;
             Neuroblastoma Risk Group (INRG) criteria, High-risk neuroblastoma defined as:&#xD;
&#xD;
               -  Stage M neuroblastoma above 365 days of age at diagnosis (no upper age limit) and&#xD;
                  Ms neuroblastoma 12-18 months old, any MYCN status* or&#xD;
&#xD;
               -  L2, M or Ms neuroblastoma with MYCN amplification, any age * In Germany, patients&#xD;
                  aged less than 18 months with stage M and without MYCN amplification will not be&#xD;
                  enrolled in HR-NBL2 trial.&#xD;
&#xD;
          2. No previous chemotherapy (except one cycle of Etoposide-Carboplatin or, in Germany and&#xD;
             Netherlands, one course of the current protocol for low/intermediate risk&#xD;
             neuroblastoma).&#xD;
&#xD;
          3. Females of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             within 7 days prior to initiation of treatment. Sexually active patients must agree to&#xD;
             use acceptable and appropriate contraception while on study drug and for one year&#xD;
             after stopping the study drug. Acceptable contraception is defined in CTFG Guidelines&#xD;
             &quot;Recommendations related to contraception and pregnancy testing in clinical trials&quot;.&#xD;
             Female patients who are lactating must agree to stop breast-feeding.&#xD;
&#xD;
          4. Written informed consent to enter the R-I randomization from patient or parents/legal&#xD;
             representative, patient, and age-appropriate assent.&#xD;
&#xD;
          5. Patient affiliated to a social security regimen or beneficiary of the same according&#xD;
             to local requirements.&#xD;
&#xD;
          6. Patients should be able and willing to comply with study visits and procedures as per&#xD;
             protocol.&#xD;
&#xD;
        In case of parents'/patient's refusal to R-I, or renal or liver toxicity, patients can&#xD;
        still be enrolled in HR-NBL2 trial with parents'/patient's consent within 3 weeks from the&#xD;
        beginning of chemotherapy. Patients will be treated with the standard induction regimen per&#xD;
        country and will be potentially eligible for subsequent randomizations.&#xD;
&#xD;
        Randomization for HDC strategy will be performed at the end of induction after the disease&#xD;
        evaluation and after surgery of the primary tumor for those patients who will receive&#xD;
        surgery before HDC.&#xD;
&#xD;
        R-HDC eligibility criteria:&#xD;
&#xD;
          1. - Stage M neuroblastoma above 365 days of age at diagnosis, any MYCN status, EXCEPT&#xD;
             patients with stage M or Ms 12-18 months old with numerical chromosomal alterations&#xD;
             only, and in complete metastatic response at the end of induction: in this case,&#xD;
             patients will have surgery but will not be eligible for R-HDC and will not be able to&#xD;
             pursue the trial.&#xD;
&#xD;
             OR&#xD;
&#xD;
             - L2, M or Ms neuroblastoma with MYCN amplification&#xD;
&#xD;
          2. Age &lt; 21 years&#xD;
&#xD;
          3. Complete response (CR) or partial response (PR) at metastatic sites:&#xD;
&#xD;
               -  Bone disease: MIBG uptake (or FDG-PET uptake for MIBG-nonavid tumors) completely&#xD;
                  resolved or SIOPEN score ≤ 3 and at least 50% reduction in mIBG score (or ≤ 3&#xD;
                  bone lesions and at least 50% reduction in number of FDG-PET-avid bone lesions&#xD;
                  for MIBG-nonavid tumors).&#xD;
&#xD;
               -  Bone marrow disease: CR and/or minimal disease (MD) according to International&#xD;
                  Neuroblastoma Response Criteria [Park JR, JCO 2017; Burchill S, Cancer 2017].&#xD;
&#xD;
               -  Other metastatic sites: complete response after induction chemotherapy +/-&#xD;
                  surgery.&#xD;
&#xD;
          4. Acceptable organ function and performance status&#xD;
&#xD;
               -  Performance status ≥ 50%.&#xD;
&#xD;
               -  Hematological status: ANC &gt; 0.5x10^9/L, platelets &gt; 20x 10^9/L&#xD;
&#xD;
               -  Cardiac function: Shortening fraction ≥ 28% or ejection fraction ≥ 55% by&#xD;
                  echocardiogram, no clinical congestive heart failure. Normal pulmonary artery&#xD;
                  pressure.&#xD;
&#xD;
               -  Normal chest X-ray and oxygen saturation.&#xD;
&#xD;
               -  Absence of any toxicity ≥ grade 3.&#xD;
&#xD;
          5. Sufficient collected stem cells available; minimum required: 6 x 10^6 CD34+ cells/kg&#xD;
             body weight stored in 3 separate fractions.&#xD;
&#xD;
          6. Written informed consent, including agreement of patient or parents/legal guardian for&#xD;
             minors, to enter the R-HDC randomization.&#xD;
&#xD;
          7. Patient affiliated to a social security regimen or beneficiary of the same according&#xD;
             to local requirements.&#xD;
&#xD;
          8. Patients should be able and willing to comply with study visits and procedures as per&#xD;
             protocol.&#xD;
&#xD;
        In case of parents'/patient's refusal, or insufficient stem cells, collection for tandem&#xD;
        HDC but with a minimum of 3 x 10^6 CD34+ cells/kg body weight, or in case of patients older&#xD;
        than 21 years, or liver or renal toxicity, HDC will consist on the standard HD Bu-Mel and&#xD;
        will be eligible for subsequent randomization.&#xD;
&#xD;
        An evaluation of the local disease will be performed after HDC and surgery:&#xD;
&#xD;
          -  In case of no local macroscopic disease, all patients will receive 21-Gy radiotherapy&#xD;
             to the pre-operative tumor bed&#xD;
&#xD;
          -  In case of local macroscopic residual disease, patients will be eligible to R-RTx if&#xD;
             the following criteria are met:&#xD;
&#xD;
               1. No evidence of disease progression after HDC/ASCR.&#xD;
&#xD;
               2. Interval between the last ASCR and radiotherapy start between 60 and 90 days.&#xD;
&#xD;
               3. Performance status greater or equal 50%.&#xD;
&#xD;
               4. Hematological status: ANC &gt; 0.5x10^9/L, platelets &gt; 20x10^9/L.&#xD;
&#xD;
               5. Written informed consent, including agreement of patient or parents/legal&#xD;
                  guardian for minors, to enter the R-RTx randomization.&#xD;
&#xD;
               6. Patient affiliated to a social security regimen or beneficiary of the same&#xD;
                  according to local requirements.&#xD;
&#xD;
               7. Patients should be able and willing to comply with study visits and procedures as&#xD;
                  per protocol.&#xD;
&#xD;
        In case of parents'/patient's refusal of the randomization, the patient will receive 21.6&#xD;
        Gy radiotherapy to the pre-operative tumor bed and pursue the next step of the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Non-inclusion criteria specific to the R-I randomization (RAPID COJEC/GPOH) :&#xD;
&#xD;
          1. Urinary outflow obstruction&#xD;
&#xD;
          2. severe arrhythmia, heart failure, previous cardiac infarct, acute inflammatory heart&#xD;
             disease&#xD;
&#xD;
          3. severe peripheral neuropathy&#xD;
&#xD;
          4. demyelinating form of Charcot-Marie-Tooth syndrome&#xD;
&#xD;
          5. hearing impairment&#xD;
&#xD;
          6. Concurrent prophylactic use of phenytoin&#xD;
&#xD;
          7. cardiorespiratory disease that contraindicates hyperhydration&#xD;
&#xD;
        Non-inclusion criteria common to all randomizations (R-I, R-HDC and R-RTx) :&#xD;
&#xD;
          1. Any negative answer concerning the inclusion criteria of R-I or R-HDC or R-RTx will&#xD;
             render the patient ineligible for the corresponding therapy phase randomization.&#xD;
             However, these patients may remain on study and be considered to receive standard&#xD;
             treatment of the respective therapy phase, and may be potentially eligible for&#xD;
             subsequent randomizations.&#xD;
&#xD;
          2. Liver function: Alanine aminotransferase (ALT) &gt; 3.0 x ULN and blood bilirubin &gt; 1.5 x&#xD;
             ULN (toxicity ≥ grade 2). In case of toxicity ≥ grade 2, call national principal&#xD;
             investigator study coordinator to discuss the feasibility.&#xD;
&#xD;
          3. Renal function: Creatinine clearance and/or GFR &lt; 60 ml/min/1.73m^2 (toxicity ≥ grade&#xD;
             2). If GFR &lt; 60 ml/min/1.73m^2, call national principal investigator to discuss.the&#xD;
             feasibility.&#xD;
&#xD;
          4. Dyspnea at rest and/or pulse oximetry &lt; 95% in air.&#xD;
&#xD;
          5. Any uncontrolled intercurrent illness or infection that in the investigator opinion&#xD;
             would impair study participation.&#xD;
&#xD;
          6. Patient under guardianship or deprived of his liberty by a judicial or administrative&#xD;
             decision or incapable of giving his consent.&#xD;
&#xD;
          7. Participating in another clinical study with an IMP while on study treatment.&#xD;
&#xD;
          8. Concomitant use with yellow fever vaccine and with live virus or bacterial vaccines.&#xD;
&#xD;
          9. Patient allergic to peanut or soya.&#xD;
&#xD;
         10. Chronic inflammatory bowel disease and/or bowel obstruction.&#xD;
&#xD;
         11. Pregnant or breastfeeding women.&#xD;
&#xD;
         12. Known hypersensitivity to the active substance or to any of the excipients of study&#xD;
             drugs known&#xD;
&#xD;
         13. Concomitant use with St John's Wort (Hypericum Perforatum).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique Valteau-Couanet, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave roussy, Paris, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique Valteau-Couanet, MD PhD</last_name>
    <phone>+33 (0)1 42 11 42 11</phone>
    <email>dominique.valteau@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Habiba Attalah, PhD</last_name>
    <phone>+33 (0)1 42 11 42 11</phone>
    <email>habiba.attalah@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Valteau-Couanet, MD PhD</last_name>
      <phone>+33 (0)1 42 11 42 11</phone>
      <email>dominique.valteau@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Attalah Habiba, PhD</last_name>
      <phone>+33 (0)1 42 11 42 11</phone>
      <email>habiba.attalah@gustaveroussy.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU d'AMIENS</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Gourmel, MD</last_name>
      <phone>+33 (0)3 22 08 76 50</phone>
      <email>gourmel.antoine@chu-amiens.Fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS &quot;Istituto Giannina Gaslini&quot;</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Garaventa Alberto, MD</last_name>
      <phone>01056362410</phone>
      <email>albertogaraventa@gaslini.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Maxima center</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lieve TyTGAT, MD</last_name>
      <phone>+31 06-55234711</phone>
      <email>G.A.M.Tytgat@prinsesmaximacentrum.nl</email>
    </contact>
    <contact_backup>
      <last_name>JAAP MUR</last_name>
      <phone>+31 06 5000 66 46</phone>
      <email>J.Mur@prinsesmaximacentrum.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University medical center Ljubljana, University Children's Hospital Ljubljana, Slovenia</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesen maja, MD</last_name>
      <phone>: 00 386 41 365 384</phone>
      <email>maja.cesenmazic@kclj.si</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau AG Klinik für Kinder und Jugendliche</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Klein-Franke, MD</last_name>
      <phone>41 62 838 92 45</phone>
      <email>Andreas.Klein-Franke@ksa.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitäts-Kinderspital beider Basel (UKBB)</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas von der Weid, Pr</last_name>
      <phone>41 61 704 17 62</phone>
      <email>nicolas.vonderweid@ukbb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Pediatria, Emato-oncologia pediatrica</name>
      <address>
        <city>Bellinzona</city>
        <zip>CH-6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierluigi Brazzola, MD</last_name>
      <phone>41 91 811 89 76</phone>
      <email>Pierluigi.Brazzola@eoc.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inselspital, Universitätsklinik für Kinderheilkunde</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jochen Rößler, MD</last_name>
      <phone>41 31 632 94 95</phone>
      <email>jochen.roessler@insel.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HUG Hôpitaux Universitaires de Genève Unité d'Hémato-Oncologie Pédiatrique</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabienne Gumy Pause, MD</last_name>
      <phone>41 79 55 32 594</phone>
      <email>fabienne.gumypause@hcuge.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUV - Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maja Beck Popovic, Pr</last_name>
      <phone>41 21 314 35 67</phone>
      <email>maja.beck-popovic@chuv.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital, Kinderspital pädiatrische Hämatologie/Onkologie</name>
      <address>
        <city>Lucerne</city>
        <zip>CH-6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Freimut H. Schilling, MD</last_name>
      <phone>+41 41 205 32 10</phone>
      <email>freimut.schilling@luks.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ostschweizer Kinderspital Hämatologie/Onkologie Claudiusstrasse 6</name>
      <address>
        <city>Saint Gallen</city>
        <zip>CH-9006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelia Vetter, MD</last_name>
      <phone>+41 71 243 13 48</phone>
      <email>cornelia.vetter@kispisg.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Pediatric Oncology Universitäts-Kinderspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabina Kroiss Benninger, MD</last_name>
      <phone>41 44 266 70 57</phone>
      <email>sabine.kroiss@kispi.uzh.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol and Weston NHS Foundation Trust</name>
      <address>
        <city>Bristol</city>
        <zip>BS1 3NU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antony NG, MD</last_name>
      <email>antony.ng@uhbristol.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Children Glasgow</name>
      <address>
        <city>Glasgow</city>
        <zip>G34</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dermot Murphy, MD</last_name>
      <email>Dermot.Murphy@ggc.scot.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Slovenia</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Vindesine</mesh_term>
    <mesh_term>Dinutuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

